BioNTech SE (BNTX) Common Equity (2018 - 2026)

BioNTech SE has reported Common Equity for 8 years, with the latest figure at $22.4 billion in Q4 2025.

• Quarterly Common Equity rose 7.88% year-over-year to $22.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.4 billion (up 7.88% YoY) and the FY2025 annual result came in at $21.7 billion, up 4.71% from the prior year.
• Common Equity advanced to $22.4 billion in Q4 2025 per BNTX's latest filing, from $21.6 billion in the prior quarter.
• Over five years, Common Equity peaked at $22.4 billion in Q4 2025 and troughed at $3.0 billion in Q1 2021.
• A 5-year average of $18.2 billion and a median of $20.6 billion in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2021 and 2025: Common Equity jumped 895.88% in 2021, then retreated 8.22% in 2025.
• Over 5 years, Common Equity stood at $13.6 billion in 2021, then soared by 50.39% to $20.5 billion in 2022, then gained by 6.46% to $21.8 billion in 2023, then fell by 4.78% to $20.7 billion in 2024, then increased by 7.88% to $22.4 billion in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $22.4 billion, $21.6 billion, and $20.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.